BLT benitec biopharma limited

if we have good clinical data by then, then it'd be abnormal not...

  1. 2,327 Posts.
    lightbulb Created with Sketch. 12
    if we have good clinical data by then, then it'd be abnormal not to have at least an equivalent valuation to our nearest competitor - say Alnylam.

    that'd be roughly $50 pps.

    also, that'd be conservative given alny's good clinical data in far smaller target markets than Benitec's pipeline.

    and Cool would be the first person in history to deliver a prediction ahead on time and budget, given he originally forecast 2017.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.